Literature DB >> 17878401

Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.

Cristina P Vicente1, Li He, Douglas M Tollefsen.   

Abstract

Heparin cofactor II (HCII) is a plasma protein that inhibits thrombin when bound to dermatan sulfate or heparin. HCII-deficient mice are viable and fertile but rapidly develop thrombosis of the carotid artery after endothelial injury. We now report the effects of HCII deficiency on atherogenesis and neointima formation. HCII-null or wild-type mice, both on an apolipoprotein E-null background, were fed an atherogenic diet for 12 weeks. HCII-null mice developed plaque areas in the aortic arch approximately 64% larger than wild-type mice despite having similar plasma lipid and glucose levels. Neointima formation was induced by mechanical dilation of the common carotid artery. Thrombin activity, determined by hirudin binding or chromogenic substrate hydrolysis within 1 hour after injury, was higher in the arterial walls of HCII-null mice than in wild-type mice. After 3 weeks, the median neointimal area was 2- to 3-fold greater in HCII-null than in wild-type mice. Dermatan sulfate administered intravenously within 48 hours after injury inhibited neointima formation in wild-type mice but had no effect in HCII-null mice. Heparin did not inhibit neointima formation. We conclude that HCII deficiency promotes atherogenesis and neointima formation and that treatment with dermatan sulfate reduces neointima formation in an HCII-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878401      PMCID: PMC2234791          DOI: 10.1182/blood-2007-04-086611

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin.

Authors:  P C Liaw; D L Becker; A R Stafford; J C Fredenburgh; J I Weitz
Journal:  J Biol Chem       Date:  2001-04-09       Impact factor: 5.157

2.  Altered vascular injury responses in mice deficient in protease-activated receptor-1.

Authors:  W M Cheung; M R D'Andrea; P Andrade-Gordon; B P Damiano
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

3.  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Authors:  Li He; Cristina P Vicente; Randal J Westrick; Daniel T Eitzman; Douglas M Tollefsen
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.

Authors:  K Tordjman; C Bernal-Mizrachi; L Zemany; S Weng; C Feng; F Zhang; T C Leone; T Coleman; D P Kelly; C F Semenkovich
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

5.  Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque.

Authors:  R A Shirk; N Parthasarathy; J D San Antonio; F C Church; W D Wagner
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

6.  Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

Authors:  P Andrade-Gordon; C K Derian; B E Maryanoff; H C Zhang; M F Addo; B P Damiano; M R D'Andrea; A L Darrow; L de Garavilla; A J Eckardt; E C Giardino; B J Haertlein; D F McComsey
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

7.  Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice.

Authors:  R J Westrick; P F Bodary; Z Xu; Y C Shen; G J Broze; D T Eitzman
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

8.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

9.  Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.

Authors:  E A McGuire; D M Tollefsen
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

Review 10.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

View more
  13 in total

Review 1.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

2.  PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice.

Authors:  Shannon M Jones; Adrien Mann; Kelsey Conrad; Keith Saum; David E Hall; Lisa M McKinney; Nathan Robbins; Joel Thompson; Abigail D Peairs; Eric Camerer; Katey J Rayner; Michael Tranter; Nigel Mackman; A Phillip Owens
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

Review 3.  Thrombin and vascular inflammation.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  Mol Cell Biochem       Date:  2011-08-23       Impact factor: 3.396

4.  Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Sumiko Yoshida; Takashi Iwase; Soichiro Tajima; Yuki Izawa-Ishizawa; Yoshitaka Kihira; Keisuke Ishizawa; Shuhei Tomita; Koichiro Tsuchiya; Masataka Sata; Masashi Akaike; Shigeaki Kato; Toshio Matsumoto; Toshiaki Tamaki
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

5.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

6.  Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.

Authors:  Jill C Rau; Carolyn Deans; Maureane R Hoffman; David B Thomas; Gray T Malcom; Arthur W Zieske; Jack P Strong; Gary G Koch; Frank C Church
Journal:  Exp Mol Pathol       Date:  2009-09-09       Impact factor: 3.362

Review 7.  Thrombin generation and atherosclerosis.

Authors:  Jana Kalz; Hugo ten Cate; Henri M H Spronk
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

8.  A rat model of thrombosis in common carotid artery induced by implantable wireless light-emitting diode device.

Authors:  Jih-Chao Yeh; Kuo-Lun Huang; Yung-Chin Hsiao; Yu-Han Hsu; Yun-Han Lin; Shyh-Liang Lou; Tsong-Hai Lee
Journal:  Biomed Res Int       Date:  2014-06-19       Impact factor: 3.411

9.  Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.

Authors:  Julian I Borissoff; Jeroen J T Otten; Sylvia Heeneman; Peter Leenders; René van Oerle; Oliver Soehnlein; Sarah T B G Loubele; Karly Hamulyák; Tilman M Hackeng; Mat J A P Daemen; Jay L Degen; Hartmut Weiler; Charles T Esmon; Joanne van Ryn; Erik A L Biessen; Henri M H Spronk; Hugo ten Cate
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

10.  Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency.

Authors:  S Le Quellec; A Desjonqueres; L Rugeri; H Desmurs Clavel; F Farhat; L Mechtouff; Y Dargaud
Journal:  Thromb J       Date:  2018-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.